Literature DB >> 29615438

Generation of Intestinal Organoids Suitable for Pharmacokinetic Studies from Human Induced Pluripotent Stem Cells.

Daichi Onozato1, Misaki Yamashita1, Anna Nakanishi1, Takumi Akagawa1, Yuriko Kida1, Isamu Ogawa1, Tadahiro Hashita1, Takahiro Iwao2, Tamihide Matsunaga1.   

Abstract

Intestinal organoids morphologically resemble intestinal tissues and are expected to be used in both regenerative medicine and drug development studies, including pharmacokinetic studies. However, the pharmacokinetic properties of these organoids remain poorly characterized. In this study, we aimed to generate pharmacokinetically functional intestinal organoids from human induced pluripotent stem (iPS) cells. Human iPS cells were induced to differentiate into the midgut and then seeded on EZSPHERE plates (AGC Techno Glass Inc., Shizuoka, Japan) to generate uniform spheroids, and the floating spheroids were subsequently differentiated into intestinal organoids using small-molecule compounds. Exposure to the small-molecule compounds potently increased the expression of intestinal markers and pharmacokinetic-related genes in the organoids, and the organoids also included various intestinal cells such as enterocytes, intestinal stem cells, goblet cells, enteroendocrine cells, Paneth cells, smooth muscle cells, and fibroblasts. Moreover, microvilli and tight junctions were observed in the organoids. Furthermore, we detected not only the expression of drug transporters but also efflux transport activity through ABCB1/MDR1 and the induction of the drug-metabolizing enzyme CYP3A4 by ligands of nuclear receptors. Our results demonstrated the successful generation of pharmacokinetically functional intestinal organoids from human iPS cells. Thus, these intestinal organoids could be used as a pharmacokinetic evaluation system in drug development studies.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29615438     DOI: 10.1124/dmd.118.080374

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  LINGO3 regulates mucosal tissue regeneration and promotes TFF2 dependent recovery from colitis.

Authors:  Kelly M Zullo; Bonnie Douglas; Nicole M Maloney; Yingbiao Ji; Yun Wei; Karl Herbine; Rachel Cohen; Christopher Pastore; Zvi Cramer; Xin Wang; Wenjie Wei; Ma Somsouk; Li Yin Hung; Christopher Lengner; Michael H Kohanski; Noam A Cohen; De'Broski R Herbert
Journal:  Scand J Gastroenterol       Date:  2021-05-03       Impact factor: 2.423

2.  Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn's disease.

Authors:  Pan Xu; Montserrat Elizalde; Ad Masclee; Marieke Pierik; Daisy Jonkers
Journal:  J Mol Med (Berl)       Date:  2021-02-11       Impact factor: 4.599

Review 3.  Gutsy science: In vitro systems of the human intestine to model oral drug disposition.

Authors:  Christopher M Arian; Tomoki Imaoka; Jade Yang; Edward J Kelly; Kenneth E Thummel
Journal:  Pharmacol Ther       Date:  2021-08-31       Impact factor: 12.310

Review 4.  Organoid technology and applications in cancer research.

Authors:  Hanxiao Xu; Xiaodong Lyu; Ming Yi; Weiheng Zhao; Yongping Song; Kongming Wu
Journal:  J Hematol Oncol       Date:  2018-09-15       Impact factor: 17.388

Review 5.  Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine.

Authors:  Hanxiao Xu; Ying Jiao; Shuang Qin; Weiheng Zhao; Qian Chu; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2018-12-05

6.  Establishment of a novel culture method for maintaining intestinal stem cells derived from human induced pluripotent stem cells.

Authors:  Satoshi Kondo; Shota Mizuno; Tadahiro Hashita; Takahiro Iwao; Tamihide Matsunaga
Journal:  Biol Open       Date:  2020-01-09       Impact factor: 2.422

7.  Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells.

Authors:  Hideki Takakura; Mano Horinaka; Ayaka Imai; Yuichi Aono; Toshimasa Nakao; Shingo Miyamoto; Yosuke Iizumi; Motoki Watanabe; Takumi Narita; Hideki Ishikawa; Michihiro Mutoh; Toshiyuki Sakai
Journal:  J Clin Biochem Nutr       Date:  2021-12-18       Impact factor: 3.114

Review 8.  The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development.

Authors:  Zhengying Zhou; Jinwei Zhu; Muhan Jiang; Lan Sang; Kun Hao; Hua He
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

9.  Inter-individual and inter-regional variations in enteric drug metabolizing enzyme activities: Results with cryopreserved human intestinal mucosal epithelia (CHIM) from the small intestines of 14 donors.

Authors:  Albert P Li; Ming-Chih D Ho; Novera Alam; Walter Mitchell; Susan Wong; Zhengyin Yan; Jane R Kenny; Cornelis E C A Hop
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 10.  The Progress of Intestinal Epithelial Models from Cell Lines to Gut-On-Chip.

Authors:  Shafaque Rahman; Mohammed Ghiboub; Joanne M Donkers; Evita van de Steeg; Eric A F van Tol; Theodorus B M Hakvoort; Wouter J de Jonge
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.